Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243399 · ClinicalTrials.gov registry record · Phase 1
Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00243399 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 10 participants.
The verdict
NCT00243399, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot).
Interventions
- DRUG Oxandrolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243399
The ClinicalTrials.gov registry entry for NCT00243399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxandrolone is the first listed.
NCT00243399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00243399 about?
NCT00243399 is a clinical study titled "Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia". The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the ...
What is the current status of trial NCT00243399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-07. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00243399?
The interventions under investigation include: Oxandrolone (DRUG).
Who is sponsoring clinical trial NCT00243399?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.